Midatech Pharma Plc | CIK:0001643918 | 3

  • Filed: 4/24/2018
  • Entity registrant name: Midatech Pharma Plc (CIK: 0001643918)
  • Generator: Novaworks Software
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1643918/000121465918002960/0001214659-18-002960-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1643918/000121465918002960/mtph-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001643918
  • Open this page in separate window: Click
  • ifrs-full:DescriptionOfAccountingPolicyForInvestmentsInJointVentures

    Joint arrangements 

    The Group is a party to a joint arrangement when there is a contractual arrangement that confers joint control over the relevant activities of the arrangement to the Group and at least one other party. Joint control is assessed under the same principles as control over subsidiaries. 

    The Group classifies its interests in joint arrangements as either: 

      · Joint ventures: where the Group has rights to only the net assets of the joint arrangement.

      · Joint operations: where the Group has both the rights to assets and obligations for the liabilities of the joint arrangement.

    In assessing the classification of interests in joint arrangements, the Group considers: 

      · The structure of the joint arrangement

      · The legal form of joint arrangements structured through a separate vehicle

      · The contractual terms of the joint arrangement agreement

      · Any other facts and circumstances (including any other contractual arrangements).

    The Group accounts for its interests in joint ventures using the equity method. The equity accounted joint venture is highly immaterial with no profit and loss impact during 2017 (2016: Nil, 2015: Nil).

    Any premium paid for an investment in a joint venture above the fair value of the Group's share of the identifiable assets, liabilities and contingent liabilities acquired is capitalised and included in the carrying amount of the investment in joint venture. Where there is objective evidence that the investment in a joint venture has been impaired the carrying amount of the investment is tested for impairment in the same way as other non-financial assets. 

    Amounts received under collaborative joint agreements, representing contributions to the Group’s research and development programmes, are recognised as a credit against research and development expense in the period over which the related costs are incurred. All costs related to these collaborative agreements are recorded as research and development expenditure. 

    The Group accounts for its interests in joint operations by recognising its share of assets, liabilities, revenues and expenses in accordance with its contractually conferred rights and obligations.